| Literature DB >> 30916127 |
Victor Dayan1, Maria José Arocena1, Amparo Fernandez1, Eloísa Silva1, Diego Pérez Zerpa1.
Abstract
INTRODUCTION: Previous cardiac surgery (PCS) is a risk factor for operative mortality in pa-tients undergoing reoperative aortic valve replacement (AVR) and may be influenced by the volume of patients in each center. The aim of this study was to evaluate the results of AVR in patients with previous cardiac surgery in a low volume cardiac center (400 cases per year).Entities:
Mesh:
Year: 2019 PMID: 30916127 PMCID: PMC6436787 DOI: 10.21470/1678-9741-2018-0251
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Clinical variables of the overall population (n=854).
| Previous surgery (70) | First surgery (784) | ||
|---|---|---|---|
| Age (years, SD) | 62.3 (15.1) | 67.1 (13.4) | 0.012 |
| Female (%) | 27 (38.6) | 368 (46.9) | 0.179 |
| Smoker (%) | 17 (24.3) | 176 (22.4) | 0.741 |
| Diabetes (%) | 19 (27.1) | 137 (17.5) | 0.045 |
| Hypertension (%) | 43 (61.4) | 541 (69.0) | 0.191 |
| Stroke (%) | 3 (4.3) | 23 (2.9) | 0.347 |
| Endocarditis (%) | 10 (14.3) | 34 (4.3) | <0.001 |
| Atrial Fibrillation (%) | 7 (10.0) | 37 (4.7) | 0.061 |
| NYHA III/IV (%) | 28 (40.0) | 277 (35.3) | 0.001 |
| LVEF (%) | 52.3 (14.6) | 57.0 (10.6) | 0.017 |
| Creatinine (mg/dl) | 1.28 (1.04) | 1.03 (0.58) | 0.03 |
| AXC (min) | 74.1 (24.6) | 61.4 (18.7) | <0.001 |
| CPB (min) | 116.4 (46.2) | 85.3 (29.6) | <0.001 |
| Total bleeding (ml) | 761 (851) | 661 (766) | 0.300 |
| Postoperative stroke (%) | 2 (2.9) | 12 (1.5) | 0.148 |
| Postoperative AF (%) | 14 (20.0) | 242 (30.9) | 0.057 |
| Permanent PM (%) | 3 (4.3) | 46 (5.9) | 0.666 |
| ICU stay (days, SD) | 3.1 (3.2) | 2.6 (3.9) | 0.395 |
| euroSCORE (SD) | 16.4 (13.4) | 6.7 (6.2) | <0.001 |
| Operative mortality (%) | 12 (17.1) | 41 (5.2) | <0.001 |
AF=atrial fibrillation; AXC=aortic cross-clamp; CABG=coronary artery bypass grafting; CPB=cardiopulmonary bypass; ICU=Intensive Care Unit; LVEF=left ventricular ejection fraction; NYHA=New York Heart Association Functional Class; PM=pacemaker
Clinical variables of the propensity matched population (n=112).
| Re-do (56) | First surgery (56) | ||
|---|---|---|---|
| Age (years, SD) | 63.1 (14.5) | 67.7 (14.9) | 0.098 |
| Female (%) | 22 (39.3) | 25 (44.6) | 0.566 |
| Smoker (%) | 14 (25.0) | 8 (14.3) | 0.154 |
| Diabetes (%) | 12 (21.4) | 7 (12.5) | 0.208 |
| Hypertension (%) | 33 (58.9) | 38 (67.9) | 0.327 |
| Stroke (%) | 2 (3.6) | 2 (3.6) | 1 |
| Endocarditis (%) | 5 (8.9) | 0 (0) | 0.022 |
| Atrial Fibrillation (%) | 6 (10.7) | 0 (0) | 0.012 |
| NYHA III/IV (%) | 18 (32.2) | 23 (41.1) | 0.534 |
| LVEF (%) | 52.5 (14.5) | 53.5 (13.3) | 0.719 |
| Creatinine (mg/dl) | 1.15 (0.53) | 1.02 (0.35) | 0.107 |
| Previous CABG (%) | 18 (32.1) | - | - |
| Previous valve surgery (%) | 25 (44.6) | - | - |
| Previous aortic surgery (%) | 4 (7.1) | - | - |
| Previous congenital surgery (%) | 8 (14.3) | - | - |
| Other previous surgery (%) | 1 (1.8) | - | - |
| AXC (min) | 72.6 (23.1) | 42.5 (10.3) | <0.001 |
| CPB (min) | 112.1 (44.2) | 68.8 (19.4) | <0.001 |
| Bioprosthesis | 35 (62.5) | 46 (82.1) | 0.09 |
| Total bleeding (ml) | 867 (898) | 649 (620) | 0.140 |
| Postoperative stroke (%) | 1 (1.8) | 2 (3.6) | 0.558 |
| Postoperative AF (%) | 14 (25.0) | 16 (28.6) | 0.670 |
| Permanent PM (%) | 2 (3.6) | 1 (1.8) | 0.558 |
| ICU stay (days, SD) | 3.3 (3.2) | 2.3 (1.6) | 0.036 |
| EuroSCORE (SD) | 15.1 (12.1) | 6.4 (4.9) | <0.001 |
| Operative mortality (%) | 7 (12.5) | 2 (3.6) | 0.082 |
AF=atrial fibrillation; AXC=aortic cross-clamp; CABG=coronary artery bypass grafting; CPB=cardiopulmonary bypass; ICU=intensive care unit; LVEF=left ventricular ejection fraction; NYHA=New York Heart Association Functional Class; PM=pacemaker
Independent predictors for operative mortality in previous cardiac surgery patients undergoing aortic valve replacement (n=70).
| Variables | OR (95%CI) | |
|---|---|---|
| Age | 1.15 (1.03-1.28) | 0.016 |
| Female | 8.5 (1.1-66.7) | 0.041 |
Fig. 1Survival in the matched population.
Independent predictors for survival in propensity matched patients with isolated aortic valve replacement (n=140).
| Variables | HR (95%CI) | |
|---|---|---|
| Age | 1.07 (1.01-1.12) | 0.012 |
| Diabetes | 2.78 (1.03-7.51) | 0.045 |
| Abbreviations, acronyms & symbols | ||||
|---|---|---|---|---|
| AF | = Atrial fibrillation | ICU | = Intensive Care Unit | |
| AVR | = Aortic valve replacement | LVEF | = Left ventricular ejection fraction | |
| AXC | = Aortic cross-clamp | NYHA | = New York Heart Association Functional Class | |
| CABG | = Coronary artery bypass grafting | PCS | = Previous cardiac surgery | |
| CPB | = Cardiopulmonary bypass | PM | = Pacemaker | |
| FTS | = First time surgery | STS | = Society for Thoracic Surgeons | |
| HC FMUSP | = Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo | TAVR | = Transcatheter aortic valve replacement | |
| HRs | = Hazard ratios | VIVID | = Valve in Valve International Data Registry | |
| Authors' roles & responsibilities | |
|---|---|
| VD | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| MJA | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| AF | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important in-tellectual content; final approval of the version to be published |
| ES | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for im-portant intellectual content; final approval of the version to be published |
| DPZ | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important in-tellectual content; final approval of the version to be published |